샘플 요청 목록

 카트 문의
시장보고서
상품코드
1757797

유행성 이하선염 백신 시장

Mumps Vaccines
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 288 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

유행성 이하선염 백신 세계 시장은 2030년까지 9억 9,350만 달러에 이를 전망

2024년에 6억 5,050만 달러로 추정되는 유행성 이하선염 백신 세계 시장은 2030년에는 9억 9,350만 달러에 이르고, 분석 기간인 2024-2030년 CAGR은 7.3%를 보일 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 단가 백신은 CAGR 9.0%를 나타내고, 분석 기간 종료시에는 4억 8,350만 달러에 이를 것으로 예측됩니다. 복합 백신 부문의 성장률은 분석 기간 중 CAGR 4.8%로 추정됩니다.

미국 시장은 1억 7,720만 달러로 추정, 중국은 CAGR 11.7%로 성장 예측

미국의 유행성 이하선염 백신 시장은 2024년에 1억 7,720만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 분석 기간인 2024-2030년 CAGR 11.7%로 2030년까지 2억 1,260만 달러 규모에 이를 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 3.5%와 7.1%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 4.9%를 보일 전망입니다.

세계의 유행성 이하선염 백신 시장 - 주요 동향과 촉진요인 정리

왜 유행성 이하선염 백신이 세계 공중보건 전략에 중요한가?

유행성 이하선염 백신은 침샘 부종, 발열, 두통, 때로는 수막염, 고환염, 난청 등의 합병증을 동반하는 전염성 바이러스성 질환인 유행성 이하선염의 발생을 예방하는 데 매우 중요한 역할을 하고 있습니다. 으로만 접종되는 이 백신은 도입 이후 전 세계 유행성이하선염 발생률을 크게 감소시켰습니다. 그러나 최근 백신 접종률이 높은 집단에서도 집단 감염이 발생함에 따라 접종률 향상과 장기적인 면역력 향상에 대한 관심이 다시금 높아지고 있습니다.

많은 국가의 정기 예방접종 프로그램에서 유행성 이하선염 백신을 유아기에 2회 접종하고, 유행하기 쉬운 지역에서는 사춘기 또는 성인기에 추가 접종을 하는 경우가 많습니다. 유행성 이하선염 백신은 광범위한 바이러스 억제 전략에서 중요한 역할을 하기 때문에 개인 예방뿐만 아니라 특히 학교, 대학, 군사 시설 및 기타 고밀도 환경에서 지역 수준의 집단 면역을 유지하는 데에도 필수적입니다.

효능과 접종률 문제를 해결하기 위해 백신 기술은 어떻게 진화하고 있는가?

현재 사용되고 있는 대부분의 약독성 생바이러스 제제는 주로 제릴린, 레닌그라드-자그레브, 우라베 등의 균주에서 유래한 것입니다. 효과적이지만, 이들 균주는 면역원성 및 방어 기간에 차이가 있어 장기적인 효과와 집단 수준의 발병 회복력에 영향을 미칠 수 있습니다. 따라서 새로운 약독화 기술, 균주 개선, 보조제 시스템 강화 등을 통해 백신의 효능을 향상시키기 위한 연구가 계속되고 있습니다.

일부 공중보건 당국은 특히 항체가가 저하된 집단에서 유행성이하선염에 대한 특이적 면역을 강화하기 위해 1가 또는 2가 부스터의 개발을 고려하고 있습니다. 저자원 환경에서 백신 섭취를 개선하기 위해 내열성 제제 및 비강 투여 시스템 개발이 진행되고 있습니다. 또한, 유전체 감시를 통해 유행 중인 유행성 이하선염 균주를 감시하고 백신 균주와 유행성 이하선염 균주의 일치도를 평가하여 예방접종 권장 사항을 업데이트하고 접종 일정을 개선하는 데 활용되고 있습니다.

시장 수요를 주도하는 지역과 인구층은?

예방접종 프로그램이 잘 확립된 고소득 국가들은 특히 소아과 일정과 학교 입학 요건을 통해 MMR 백신에 대한 수요를 지속적으로 주도하고 있습니다. 그러나 대학과 의료 현장에서 유행성 이하선염이 유행함에 따라 성인용 부스터 프로그램도 확대되고 있습니다. 신흥 경제국에서는 정기 예방접종 확대 노력이 남미, 사하라 사막 이남 아프리카, 라틴아메리카를 포함한 MMR 백신의 1차 수요를 견인하고 있습니다.

분쟁 지역이나 의료 인프라가 단절된 지역의 주민들도 국제 원조와 집단 예방접종 캠페인을 통해 유행성 이하선염 백신 접종의 우선순위 대상이 되고 있습니다. 계절이나 여행에 따른 백신 접종 급증은 이주민이 유입되거나 대규모 국제 행사가 개최되는 국가에서 볼 수 있습니다. 백신으로 예방할 수 있는 질병에 대한 인식이 개선되고 전 세계적으로 예방접종에 대한 자금이 증가함에 따라, 공공 및 민간 의료 시스템 모두 유행성 이하선염 예방에 집중하고 있습니다.

유행성 이하선염 백신 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다. .

유행성 이하선염 백신 시장의 성장은 전 세계 예방접종 활동 증가, 인구 밀집 지역에서 유행성이하선염의 재유행, 유행성이하선염과 관련된 합병증에 대한 인식 확대 등 여러 요인에 의해 주도되고 있습니다. 백신 제제, 콜드체인 물류, 균주 최적화에 대한 기술 발전으로 백신 효능과 접근성이 모두 향상되고 있습니다. 소아 및 청소년 의료에 대한 투자 증가, 감시 기반 강화, 국가 예방접종 가이드라인의 업데이트도 수요를 뒷받침하고 있습니다. 의료 시스템이 감염병 대비와 백신의 보편적 접종을 우선시함에 따라 유행성 이하선염 백신 시장은 선진국과 신흥국 모두에서 지속적인 성장세를 보일 것으로 예측됩니다.

부문

제품 유형(1가, 혼합, 2가, 3가, 기타 제품 유형);최종사용자(소아과 클리닉, 병원, NGO, 기타 최종사용자)

조사 대상 기업 예(총 42개사)

  • Bharat Biotech
  • Bio Farma
  • China Bio-Immunity Corporation
  • GlaxoSmithKline plc(GSK)
  • Haffkine Bio-Pharmaceutical Corp.
  • Indian Immunologicals Ltd.
  • Instituto Butantan
  • Kitasato Daiichi Sankyo Vaccine Co., Ltd.
  • LG Chem
  • Merck & Co., Inc.
  • Microgen
  • Panacea Biotec Ltd.
  • Sanofi Pasteur
  • Serum Institute of India Pvt. Ltd.
  • Shanghai Institute of Biological Products
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Ltd.
  • The Research Institute for Biological Safety Problems
  • Torii Pharmaceutical Co., Ltd.
  • Zydus Lifesciences Ltd.

AI 통합

우리는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM이나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.07.03

Global Mumps Vaccines Market to Reach US$993.5 Million by 2030

The global market for Mumps Vaccines estimated at US$650.5 Million in the year 2024, is expected to reach US$993.5 Million by 2030, growing at a CAGR of 7.3% over the analysis period 2024-2030. Monovalent, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$483.5 Million by the end of the analysis period. Growth in the Combinational segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$177.2 Million While China is Forecast to Grow at 11.7% CAGR

The Mumps Vaccines market in the U.S. is estimated at US$177.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$212.6 Million by the year 2030 trailing a CAGR of 11.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.5% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global Mumps Vaccines Market - Key Trends & Drivers Summarized

Why Are Mumps Vaccines Critical to Global Public Health Strategies?

Mumps vaccines play a pivotal role in preventing outbreaks of mumps, a contagious viral disease characterized by swelling of the salivary glands, fever, headache, and in some cases, complications such as meningitis, orchitis, and hearing loss. The vaccine-commonly administered as part of the MMR (measles, mumps, and rubella) combination-has significantly reduced global mumps incidence since its introduction. However, recent outbreaks, even in highly vaccinated populations, have reignited the focus on improving coverage and long-term immunity.

Routine immunization programs in many countries include the mumps vaccine as a two-dose schedule during early childhood, often reinforced with booster doses in adolescence or adulthood in outbreak-prone regions. Because of its role in broader viral containment strategies, the mumps vaccine is not only critical for individual protection but also essential for maintaining community-level herd immunity-particularly in schools, universities, military installations, and other high-density environments.

How Are Vaccine Technologies Evolving to Address Efficacy and Coverage Challenges?

Most mumps vaccines in use today are live attenuated virus formulations, primarily derived from strains such as Jeryl Lynn, Leningrad-Zagreb, or Urabe. While effective, these strains exhibit varying immunogenicity and duration of protection, which can influence long-term effectiveness and population-level outbreak resilience. As a result, research is ongoing into improving vaccine efficacy through new attenuation techniques, strain modification, and enhanced adjuvant systems.

Some public health authorities are also exploring the development of monovalent or bivalent boosters to augment mumps-specific immunity, especially in populations experiencing waning antibody levels. Efforts to develop thermostable formulations and intranasal delivery systems are under way to improve vaccine uptake in low-resource settings. Moreover, genomic surveillance is being used to monitor circulating mumps strains and assess vaccine-strain match, helping update recommendations and refine immunization schedules.

Which Regions and Demographic Groups Are Driving Market Demand?

High-income countries with established immunization programs continue to drive demand for MMR vaccines, particularly through pediatric schedules and school-entry requirements. However, adult booster programs are expanding in response to mumps outbreaks in universities and healthcare settings. In emerging economies, efforts to scale up routine immunization coverage are boosting primary demand for the MMR vaccine, including in parts of South Asia, Sub-Saharan Africa, and Latin America.

Populations in conflict zones or regions with disrupted healthcare infrastructure are also priority targets for mumps vaccination through international aid and mass immunization campaigns. Seasonal and travel-based vaccination spikes are seen in countries that experience migratory influxes or host large international events. As awareness of vaccine-preventable diseases improves and global immunization funding increases, both public and private healthcare systems are intensifying their focus on mumps control.

The Growth in the Mumps Vaccines Market Is Driven by Several Factors…

The growth in the mumps vaccines market is driven by several factors including increasing global immunization efforts, resurgence of mumps outbreaks in highly populated areas, and expanded awareness of complications associated with the disease. Technological advances in vaccine formulation, cold chain logistics, and strain optimization are improving both efficacy and accessibility. Rising investments in pediatric and adolescent health, enhanced surveillance infrastructure, and updated national immunization guidelines are also supporting demand. As healthcare systems prioritize infectious disease preparedness and universal vaccine coverage, the mumps vaccine market is set for sustained growth across both developed and developing economies.

SCOPE OF STUDY:

The report analyzes the Mumps Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Monovalent, Combinational, Divalent, Trivalent, Other Product Types); End-Use (Pediatric Clinics, Hospitals, NGOs, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Bharat Biotech
  • Bio Farma
  • China Bio-Immunity Corporation
  • GlaxoSmithKline plc (GSK)
  • Haffkine Bio-Pharmaceutical Corp.
  • Indian Immunologicals Ltd.
  • Instituto Butantan
  • Kitasato Daiichi Sankyo Vaccine Co., Ltd.
  • LG Chem
  • Merck & Co., Inc.
  • Microgen
  • Panacea Biotec Ltd.
  • Sanofi Pasteur
  • Serum Institute of India Pvt. Ltd.
  • Shanghai Institute of Biological Products
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Ltd.
  • The Research Institute for Biological Safety Problems
  • Torii Pharmaceutical Co., Ltd.
  • Zydus Lifesciences Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Mumps Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Mumps Outbreaks in Vaccinated Populations Drives Booster Dose Recommendations
    • Increased Global Immunization Coverage Supports Continued Demand for MMR and MMRV Combination Vaccines
    • OEM Focus on Enhancing Immunogenicity and Long-Term Protection Improves Vaccine Formulations
    • Push for School and Workplace Immunization Requirements Sustains High Uptake of Mumps Vaccines
    • WHO and UNICEF Procurement Programs Expand Access in Developing Regions Through Gavi Partnerships
    • Growth in Travel and International Student Populations Spurs Pre-Travel Mumps Immunization Demand
    • OEM Development of Thermostable and Liquid Vaccine Formats Enhances Cold Chain Resilience
    • Increased Surveillance and Epidemiological Tracking Improve Targeting of High-Risk Populations
    • Rising Demand for Two-Dose and Catch-Up Immunization Schedules Strengthens Booster Market
    • Global Push for Measles and Rubella Elimination Encourages Ongoing Inclusion of Mumps in Combination Shots
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Mumps Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Mumps Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Mumps Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Mumps Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Monovalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Monovalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Monovalent by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Combinational by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Combinational by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Combinational by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Divalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Divalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Divalent by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Trivalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Trivalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Trivalent by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pediatric Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Pediatric Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Pediatric Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for NGOs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for NGOs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for NGOs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Mumps Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Mumps Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Mumps Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Mumps Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Mumps Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Mumps Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Mumps Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Mumps Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Mumps Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Mumps Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Spain 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Russia 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Mumps Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Mumps Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Mumps Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Mumps Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Mumps Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Australia 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Mumps Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: India 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: South Korea 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Mumps Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Mumps Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Mumps Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Mumps Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Argentina 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Brazil 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Mexico 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Mumps Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Mumps Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Mumps Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Mumps Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Iran 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Israel 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: UAE 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Mumps Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Africa 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제